Malaria vaccinations have been available for decades, but the exact treatment is still unknown. While there are several vaccinations available to prevent mosquitos from transmitting illness, there is no known treatment for malaria. As a result, many individuals prefer to take precautions and utilize malaria preventive medicines to keep themselves safe.
GlaxoSmithKline manufactures RTS, or Respiratory Trips and Tracheal, one of the most common malaria vaccines. RTS, marketed under the trade name Mosquirax, is the only authorized malaria vaccine as of now. It has very poor efficiency, requires four injections, and requires a series of monitoring to ensure proper administration. As a result, many individuals choose alternate items, such as insect repellents or other natural prophylactic methods. The University of Pennsylvania and Acuitas Therapeutics will work with the Walter Reed Army Institute of Research and the Naval Medical Research Center to develop an mRNA-based malaria vaccine in June 2021. The trivalent dosage of V pneumonovirus (TVP), also manufactured by GlaxoSmithKline, is the second most common malaria vaccine. This vaccination is less effective than RTS, but it has a lower risk of adverse effects. The trivalent V pneumonovirus dosage is also delivered as an aerosol spray, making it less likely to be inhaled by vulnerable persons.
Poor supply chains and distribution networks in some malaria-affected emerging nations are impeding the commercial penetration of malaria vaccines in these countries. On the contrary, rising malaria occurrences, as well as the availability of several companies launching low-profit margin vaccines throughout the world, are some of the key factors driving the malaria vaccines market. Furthermore, rising awareness of the disease's consequences continued R&D in this field, and increased funding from governments in both developing and developed countries are all boosting the malaria vaccines market. Sanaria stated in June 2021 that its PfSPZ vaccine is efficacious and safe against malaria after its Phase III clinical trial.